Percutaneous Nephrolithotomy Market Report 2026

The percutaneous nephrolithotomy market size has grown strongly in recent years. It will grow from $19.39 billion in 2025 to $21.07 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to high prevalence of kidney stones, limited minimally invasive surgical options, reliance on open surgery for complex stones, lack of awareness of PCNL benefits, high recurrence rates of renal calculi.

The percutaneous nephrolithotomy market size is expected to see strong growth in the next few years. It will grow to $28.42 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to advancements in flexible and miniaturized nephrolithotomy devices, increasing adoption of minimally invasive urology procedures, expansion of ambulatory surgical centers and clinics, rising patient awareness regarding treatment options, integration of advanced imaging and monitoring systems in procedures. Major trends in the forecast period include increasing use of ai for preoperative planning and stone removal prediction, rising integration of cloud and big data for patient and procedure management, growing use of iot-enabled devices for real-time monitoring during pcnl procedures, increasing implementation of smart manufacturing for pcnl devices and accessories, rising adoption of precision medicine approaches for personalized stone management.

The rising prevalence of renal diseases is expected to drive the growth of the percutaneous nephrolithotomy market in the coming years. Renal diseases encompass a wide range of conditions that affect kidney function and impair the kidneys’ ability to operate effectively. The increasing burden of renal diseases is linked to factors such as higher rates of diabetes and hypertension, an aging population, unhealthy lifestyle habits, genetic susceptibility, chronic health conditions, and improved awareness and diagnosis. Percutaneous nephrolithotomy supports the management of renal diseases by offering a minimally invasive surgical option for removing large or complex kidney stones, relieving pain, reducing the risk of urinary tract infections, and improving overall kidney function. For instance, in May 2024, according to Kidney Care UK, a UK-based non-profit charity, more than 20 people in the United Kingdom develop kidney failure each day. Therefore, the growing prevalence of renal diseases is contributing to the expansion of the percutaneous nephrolithotomy market.

The growing adoption of minimally invasive surgeries is also expected to propel the growth of the percutaneous nephrolithotomy market going forward. Minimally invasive surgeries are medical procedures that involve limited incisions to diagnose or treat medical conditions, offering several advantages over traditional open surgeries. The increasing preference for minimally invasive approaches is driven by benefits such as shorter recovery times and hospital stays, reduced risk of complications, less postoperative pain and scarring, and improved precision enabled by advanced technologies. These advantages significantly support the use of percutaneous nephrolithotomy as a less invasive method for treating kidney stones. For instance, in April 2025, according to reports published by Intuitive Surgical Inc., a US-based manufacturer of robotic systems, hospitals that adopted robotic-assisted surgery experienced an increase in minimally invasive surgery rates from 60.5% to 65.8%, compared to a smaller increase from 56.1% to 57% in hospitals that did not implement robotic systems. Therefore, the increasing adoption of minimally invasive surgeries is driving the growth of the percutaneous nephrolithotomy market.

Major companies operating in the percutaneous nephrolithotomy market are concentrating on adopting advanced technologies such as robot-assisted surgical platforms to improve surgical accuracy and patient outcomes. Robot-assisted surgical platforms are sophisticated medical systems that use robotic technology to help surgeons perform complex procedures with enhanced precision, control, and flexibility. For example, in February 2023, Ethicon Inc., a US-based medical technology company, reported the successful robotic-assisted removal of kidney stones in the first patient using the MONARCH platform for urology. This platform enables urologists to navigate the kidney with robotic assistance through a handheld controller and supports both ureteroscopic and percutaneous nephrolithotomy procedures. It offers improved navigation, access, stone clearance, and procedural control compared to conventional techniques.

Major companies operating in the percutaneous nephrolithotomy market are Boston Scientific Corporation, Olympus Corporation, Cook Medical, Karl Storz SE And Co. KG, Merit Medical Systems, Richard Wolf GmbH, Dornier MedTech, EDAP TMS, ELMED Lithotripsy Systems, Advin Urology, Siemens Healthineers AG, Stryker Corporation, Lumenis Ltd, HealthTronics Inc, Rocamed SAM, Quanta System S.p.A, GEMMS Co Ltd, Pusen Medical Technology Co Ltd, Storz Medical AG, Jena Med Tech, Shenzhen Hyde Medical Equipment, Allium Medical Solutions Ltd, Medtronic plc, Nanjing Minimally Invasive Medical Technology Co Ltd.

North America was the largest region in the percutaneous nephrolithotomy market in 2025. The regions covered in the percutaneous nephrolithotomy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the percutaneous nephrolithotomy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the percutaneous nephrolithotomy market by increasing the costs of imported devices, surgical instruments, and accessories, particularly in North America and Europe. These tariffs have temporarily slowed adoption in hospitals and ambulatory surgical centers, but have also encouraged local manufacturing, promoted innovation in cost-effective device designs, and improved supply chain resilience for kidney stone treatment solutions.

The percutaneous nephrolithotomy market research report is one of a series of new reports that provides percutaneous nephrolithotomy market statistics, including percutaneous nephrolithotomy industry global market size, regional shares, competitors with a percutaneous nephrolithotomy market share, detailed percutaneous nephrolithotomy market segments, market trends and opportunities, and any further data you may need to thrive in the percutaneous nephrolithotomy industry. This percutaneous nephrolithotomy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Percutaneous nephrolithotomy (PCNL) is a minimally invasive surgical technique used to remove kidney stones, also known as renal calculi, from the urinary tract. The procedure involves creating a small incision in the skin and forming a direct access pathway to the kidney, through which specialized instruments are inserted to fragment and remove the stones. PCNL is typically performed when less invasive treatment options, such as shock wave lithotripsy or ureteroscopy, are ineffective or not appropriate.

The main types of percutaneous nephrolithotomy are categorized based on stone composition, including magnesium ammonium phosphate stones, calcareous stones, and uric acid calculi. Magnesium ammonium phosphate stones are a specific type of kidney stone formed from magnesium, ammonium, and phosphate ions. The procedure involves various components such as accessories, devices, and related services, which are utilized across end users including ambulatory surgical centers, clinics, and hospitals.

The percutaneous nephrolithotomy market consists of revenues earned by entities by providing services such as preoperative consultation and assessment, imaging services, anesthesia services, and postoperative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The percutaneous nephrolithotomy market also includes sales of nephroscopes, lithotripters, and guidewires. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.